The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines (Lundbeck)

European Commission fines Lundbeck and other pharmaceutical companies for delaying market entry of generic medicines* On 19 June 2013 the European Commission issued a press release stating that it had imposed fines in the amount of € 93,8 million on Lundbeck (a Danish pharmaceutical company) and € 52,2 million on manufacturers of other generic medicines that were producing a cheaper and generic version of Lundbeck’s brand-drug citalopram. The generics manufacturers were notably Alpharma (now part of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Ashurst (Milan)
  • RSM US (New York)

Quotation

Gabriele Accardo, Anthony Reda, The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines (Lundbeck), 19 June 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 57743

Visites 279

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues